BACKGROUND: @entity4672 withdrawal for 3 months might permit estrogenic stimulation in residual resistant @entity0 susceptible to @entity4672 reintroduction. We investigated the impact of a 3-month @entity4672 -free interval on serum @entity53 levels in @entity1 with early stage @entity0 . @entity1 AND METHODS: Postmenopausal @entity1 with @entity172 receptor- and/or @entity1420 receptor-positive (> 10% of immunoreactive cells), node-negative early @entity0 were eligible. @entity1 received @entity4672 for 5 years with a 3-month treatment-free interval after the first year of therapy. The primary end point was to evaluate the increase in serum @entity53 levels after a 3-month treatment-free interval. The secondary end points were the evaluations of other biologic markers (eg,  follicle-stimulating hormone, luteinizing hormone, @entity165 , high-density lipoprotein, @entity1674 , osteocalcin). RESULTS: From November 2007 to February 2012, 130 evaluable @entity1 were enrolled. The median age was 61  years. Mean values of @entity53 levels at time of discontinuation were 5.6 pg/mL (standard deviation 1.7). @entity53 levels increased after a 3-month treatment-free interval by a mean of 3.3 pg/mL (66%; P  < .0001). Follicle-stimulating hormone and luteinizing hormone levels decreased from baseline by a mean of 7.5 mU/mL (P  < .0001), and 1.4 mU/mL (P  = .0062), respectively. @entity1674 decreased from baseline by a mean of 8.6 mg/dL (P  = .036), and osteocalcin increased by a mean of 2.8 ng/mL (P  = .013). CONCLUSION: Intermittent @entity4672 significantly affects @entity53 levels.

Intermittent XXXX Administration as Adjuvant Endocrine Therapy for Postmenopausal @entity1 With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'PATIENTS'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity4672 :: ('MESH:C067431', 'Chemical') :: ['letrozole', 'Letrozole'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast cancer disease'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['Triglycerides', 'triglycerides'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['Estradiol', 'estradiol'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity4672 :: (MESH:C067431,Chemical) :: ['Letrozole']
